Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

Key facts

Sponsor

Sanguine Biosciences

Principal Investigator

Andrew C Frisina, M.S.

Sanguine Biosciences

Intervention

Specimen Donation(diagnostic_test)

Enrollment

4 enrolled

Eligibility

18-85 years · All sexes

Timeline

2023 – 2024

Study locations (1)

• Sanguine Biosciences, Woburn, Massachusetts, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fanconi anemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06744283
  Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06648096
  Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• RECRUITINGNANCT05687149
  Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
  National Cancer Institute (NCI)
• RECRUITINGNANCT05973656
  Role of Acetaldehyde in the Development of Oral Cancer
  Masonic Cancer Center, University of Minnesota
• RECRUITINGPHASE1, PHASE2NCT04784052
  Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
  Porteus, Matthew, MD
• ACTIVE NOT RECRUITINGPHASE2NCT04248439
  Gene Therapy for Fanconi Anemia, Complementation Group A
  Rocket Pharmaceuticals Inc.
• ACTIVE NOT RECRUITINGNANCT04437771
  Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
  Rocket Pharmaceuticals Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT04069533
  Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A
  Rocket Pharmaceuticals Inc.

See all trials for Fanconi anemia →